Aclaris' skin tumor compound meets in Phase II

Dermatology company Aclaris Therapeutics Inc. (Malvern, Pa.), announced positive Phase II results for topical A-101 to treat seborrheic keratosis. The double-blind, U.S. Phase II trial in 35 patients with seborrheic keratosis showed that 32.5% and 40% topical A-101 each met the primary endpoint of clearance of lesions on the back based on the physician lesion assessment scale at day 78 vs. placebo. The 25% concentration of A-101 missed the primary endpoint. A-101 was well tolerated at all concentrations. ...